Common Variable Immunodeficiency at the End of a Prospering Decade: Towards Novel Gene Defects and Beyond

Hermann Eibel; Ulrich Salzer; Klaus Warnatz


Curr Opin Allergy Clin Immunol. 2010;10(6):526-533. 

In This Article


Analyzing responses of B and T cells from 32 CVID and 10 IgA-deficient (IgAD) patients to various combinations of anti-CD40, IL4, and IL21, Borte et al.[54] reported almost normal in-vitro formation of antibody secreting cells, class switch and IgG secretion for B cells from CVID patients, when IL21 was added to the cultures. Applying the same conditions, IgA secretion by B cells from IgAD patients was not restored to the extent as found for the CVID B cells. Genetic defects in the IL21 and IL21R genes were not found in the CVID patients.

The significance of the finding that IL21 may be a potent inducer of antibody production in CVID is to some extent limited due to the fact that 40% of the individuals were, according to the Freiburg classification, CVID subgroup II patients who have nearly normal switched memory B cells and who are known to often show normal B-cell responses in vitro.[54] Thus, it remains open whether IL21 can develop into a therapeutic option in CVID.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.